Pharmstandard International’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Pharmstandard International’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	$3.67M	Hold	565,063	–	–	12.65%	4
2018 Q2	$4.33M	Sell	565,063 -97,000	-15%	-$1.4M	17.36%	3
2018 Q1	$14.8M	Hold	662,063	–	–	37.17%	1
2017 Q4	$8.44K	Hold	662,063	–	–	8.68%	5
2017 Q3	$10.3M	Hold	662,063	–	–	30.07%	2
2017 Q2	$9.29M	Hold	662,063	–	–	32.21%	2
2017 Q1	$14.6M	Buy	+662,063	New	+$14M	38.85%	1

Other funds holding JNCE

TGI

TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return

TGI

TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Pharmstandard International's JNCE Position: Q3 2018 in Review

Pharmstandard International held its Jounce Therapeutics, Inc. Common Stock (JNCE) position steady in Q3 2018 at 565,063 shares worth $3.67M. The position accounts for 12.65% of the portfolio, ranked #4.

Pharmstandard International first reported a position in JNCE in Q1 2017 and has held it in 7 quarters since. The position peaked at $14.8M in Q1 2018. 85 funds tracked by Wall St. Rank hold JNCE as of Q3 2018.

Pharmstandard International held 565,063 shares of Jounce Therapeutics, Inc. Common Stock worth $3.67M as of Q3 2018.
Pharmstandard International left its Jounce Therapeutics, Inc. Common Stock share count unchanged in Q3 2018.
Jounce Therapeutics, Inc. Common Stock made up 12.65% of Pharmstandard International's portfolio in Q3 2018, its #4 holding.
Pharmstandard International first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2017 and has held it in 7 quarters since.
Pharmstandard International's Jounce Therapeutics, Inc. Common Stock position peaked at $14.8M in Q1 2018.
85 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q3 2018.

Based on Pharmstandard International's 13F filing for Q3 2018, filed 15 Nov 2018.